INTRODUCTION
Ecabet sodium, a dehydroabietic acid derivative from pine resin (Figure 1 ), has been used clinically for the treatment of gastritis and gastric ulcer [1] . Ecabet is a locally acting anti-ulcer agent with a high affinity for the stomach wall [2] . It has also been shown, in animal experimental models of colorectal cancer, that ecabet sodium may slow the development of the mucosal dysplasia-invasive adenocarcinoma sequence [3] . Ecabet is believed to exert its effects through a series of mechanisms. (1) Anti-bacterial effects. Triple therapy with amoxicillin, ecabet and a proton pump inhibitor effectively eradicated H. pylori [4, 5] . Ecabet prevents the survival of H. pylori in the stomach via inhibition of essential urease activity [6, 7] , and inhibits the adhesion of H. pylori to gastric epithelia [8] . (2) Enhanced mucosal protection and repair. Ecabet stimulates re-epithelization after mucosal damage [9] and binds strongly to the gastric mucus layer [10] . (3) Inhibition of pepsin activity. Ecabet binds to and precipitates pig pepsin [11] and, by coating the mucus gel, can prevent its mucolysis by pepsin [12] .
The protective adherent gastroduodenal mucus\ bicarbonate barrier is the first line of defence, protecting the underlying epithelial cells from damage by luminal aggressors (e.g. acid and pepsin). In the healthy human stomach, mucus gel is present as a continuous layer omean (S.D.) thickness 144 (52) µm [13] q, which is maintained by a dynamic balance between secretion from the epithelial cells and erosion from the surface into the lumen. The adherent gastric mucus barrier has been shown to be structurally weaker in patients with peptic ulcer [14] . This structural weakness is caused by a decrease in the content of polymeric, gel-forming Ecabet sodium is [(j)-(1R,4aS,10aR )-1,2,3,4,4a,9,10,10a-octahydro-1,4a-dimethyl-7-(1-methylethyl)-6-sulpho-1-phenanthrenecarboxylic acid 6-sodium salt pentahydrate].
mucins : decreases of 48 % in patients with gastric ulcer and 18 % in patients with H. pylori-induced gastritis have been recorded compared with controls [14, 15] . Associated with the decrease in the strength of the gel in peptic ulcer disease is a change in the pepsin isoenzyme profile in the gastric juice. Seven pepsins (1, 2, 3, 3a, 4, 5 and 6) have been identified in human gastric juice, with pepsin 3 being the most abundant [16] . The pepsin 1 content increases from 3.6 % of total pepsin activity in pentagastrin-stimulated gastric juice from non-ulcer controls to between 16.5 % and 23 % in patients with peptic ulcer [17] . This pepsin has been shown to be up to 6 times more mucolytic than pepsin 3 [18] . Therefore gastric juice from peptic ulcer patients could be mucolytic enough to tip the balance in favour of erosion of the mucus barrier, leading to mucosal damage and ulceration. It is therefore important to determine the ability of ecabet to inhibit individual pepsins. Here we report the first study on the inhibition of pepsin activity by ecabet in basal and pentagastrin-stimulated gastric juice, and the effects of ecabet on individual human pepsins 1, 3 and 5.
MATERIALS AND METHODS

Materials
Ecabet sodium was obtained from Tanabe Seiyaku Co. Ltd (Osaka, Japan). All other reagents were of analytical grade, and were obtained from Sigma Chemical Co. (Poole, Dorset, U.K.).
Human gastric juice
Gastric juice was obtained via a naso-gastric tube from nine patients investigated for reflux oesophagitis, and from 12 non-symptomatic volunteers. Two samples were obtained : a basal sample collected over 30 min before pentagastrin stimulation (6 µg\kg subcutaneously), and a 60 min post-pentagastrin sample. The subjects had fasted overnight, and had stopped anti-secretory treatment 5 days before collection. The juice samples were dialysed twice against 2 litres of 0.05 M sodium acetate buffer, pH 4.1, at 4 mC for 24 h. Each juice sample was divided into 8 ml aliquots and stored at either 4 mC or k20 mC.
Measurement of proteolytic activity
The proteolytic activity of human gastric juice samples was measured : (1) using bovine haemoglobin as a substrate at pH 2.0 [19] ; and (2) using succinyl albumin as a substrate at pH 2.2, a modification of the method of Lin et al. [20, 21] . Both of these assays used pig pepsin as a standard.
Effect of ecabet on pepsin proteolytic activity
A 200 µl sample of pig pepsin or pepsinogen solution (1 mg\ml) was incubated with 200 µl of ecabet, to give a final concentration of 0-10 mg\ml ecabet, for 30 min at 37 mC at pH 1.6 (0.1 M glycine\HCl and 0.05 M NaCl) or pH 5.0 (0.05 M sodium acetate buffer containing 0.1 M NaCl) for pepsin solutions, or at pH 7.4 (0.067 M sodium phosphate buffer) for pepsinogen solutions. The suspensions were then centrifuged for 10 min at 1200 g in a bench centrifuge. Pepsin activity in the supernatant was measured using bovine haemoglobin as a substrate.
For investigations of pepsin activity in gastric juice, 1 ml of gastric juice (pepsin activity range 20-260 µg\ml) was mixed with ecabet to give a final concentration of 5 mg\ml ecabet, and incubated for 30 min at 37 mC at pH 1.6 or pH 5.0. A 0.5 ml portion of human pepsin isoenzymes 1, 3 and 5 (containing 200 or 400 µg\ml pepsin) was mixed with ecabet to give a final ecabet concentration of 5 mg\ml, followed by incubation for 30 min at 37 mC at pH 1.6 or pH 5.0. The suspensions were then processed as above, with the exception that measurements of enzyme activity involved the production of a new N-terminal peptide from succinyl albumin.
The statistical test used to compare the different groups was a Mann-Whitney U test, with significance set at P 0.05.
Preparation of human pepsin isoenzymes
Pepsins in gastric juice were fractionated by HPLC using an anion-exchange TSK DEAE-5PW gel with a linear gradient of 50-300 mM NaCl in 50 mM acetate buffer, pH 4.1, over 30 min, followed by a single step to 1 M NaCl in the same buffer. Pepsin 5 was eluted between 50 and 100 mM NaCl, pepsin 3 between 100 and 200 mM NaCl, and pepsin 1 between 450 and 650 mM NaCl [22] . Inhibition of pepsin by ecabet sodium Table 1 Effects of ecabet on pepsin activity in pentagastrin-stimulated gastric juice Pepsin activity is expressed in µg/ml, and was measured using the N-terminal assay (n l 3 for each assay). The symbols j and k represent the presence and absence respectively of a preincubation step with 5 mg/ml ecabet. The prefix P denotes a patient with reflux oesophagitis, and the prefix V denotes a non-symptomatic volunteer. ' Activity (%) ' is the percentage activity remaining after ecabet treatment. (The supernatant produced from centrifugation of 5 mg/ml ecabet alone had no effect in the N-terminal assay.) The isoenzyme solutions were dialysed exhaustively against distilled water and then freeze-dried.
Effect of ecabet on the mucolytic activity of pepsin
Gastric juice at pH 4.0 was incubated at 37 mC for 30 min with or without ecabet (5 mg\ml). The samples were then centrifuged at 1200 g, and the supernatant was dialysed against 0.1 M glycine\HCl buffer, pH 1.6, containing 0.05 M NaCl. A 0.5 ml sample of the supernatant was incubated with a 2 ml solution of purified pig gastric mucin at pH 1.6 [21] (final mucin concentration 4-6 mg\ml). Mucolytic activity was measured at 37 mC against time, using a Contraves low-shear 30 viscometer [23] . The results were expressed as the percentage decrease in specific viscosity after 1 h of incubation. The percentage decreases were corrected for any non-pepsininduced changes in the viscosity of the mucin solution. The statistical comparison used was a Wilcoxon paired test, with significance set at P 0.05.
Mucin-ecabet interaction studies
Solutions of pig gastric mucin (10 mg\ml), at pH 1.6 and pH 5.0 (buffers as in the proteolytic activity section), purified by CsCl equilibrium density centrifugation followed by exclusion on Sepharose CL-2B, were mixed with solid ecabet sodium to give final ecabet concentrations of between 0.5 and 10 mg\ml. The mixture was preincubated at 37 mC for 3 h in a shaking water bath, and viscosity was measured using a Contraves low-shear viscometer at 37 mC. The results were expressed as percentage synergism, calculated using the equation :
where M is mucin viscosity, E is ecabet viscosity and ME is the measured viscosity of the mixture. A positive synergism indicates an interaction between mucin and ecabet that enhances viscosity.
RESULTS
Inhibition of pepsin and of pepsin activity derived from pepsinogen
Preincubation of pig pepsin with ecabet at concentrations up to 10 mg\ml at pH 1.6 or pH 5.0 had no effect on the pepsin activity measured at pH 2.0 using bovine haemoglobin as substrate (e.g. only 3-6 % of the activity was lost following a 30 min preincubation at pH 5.0 with the highest concentrations of ecabet). However, a marked decrease in pepsin activity from pepsinogen was observed : 85 % and 90 % decreases were measured following preincubation with 5 and 10 mg\ml ecabet respectively at pH 7.4. When ecabet sodium was preincubated with pentagastrin-stimulated gastric juice from patients with reflux oesophagitis, and the pepsin activity remaining in the supernatant was assessed by new N-terminal development using succinyl albumin as the substrate, significant inhibition occurred at both preincubation pH values ( Table 1 ). The mean activity remaining was 36.9p4.8 % (pS.E.M. ; n l 8) and 21.7p7.7 % after preincubation with 5 mg\ml ecabet at pH 1.6 and pH 5.0 respectively. The inhibition data, when plotted, showed a skewed distribution, and therefore a non-parametric statistical test was used. The effect of ecabet was not significantly different between the two pH values. Pepsin activity in pentagastrin-stimulated gastric juice from nonsymptomatic volunteers also showed a significant decrease after treatment with 5 mg\ml ecabet : the mean activity remaining was 53.9p6.6 % and 59.8p5.0 % (n l 7) after preincubation at pH 1.6 and pH 5.0 respectively. As with the patient samples, the effect of ecabet was not significantly different between pH 1.6 and pH 5.0. However, there were significant differences between the patient and volunteer groups : (1) pentagastrin-stimulated gastric juice from patients showed significantly more inhibition by ecabet at pH 1.6 than did volunteer juice at pH 5.0 ; and (2) pentagastrin-stimulated gastric juice from patients showed significantly more inhibition by ecabet at pH 5.0 than did volunteer juice at pH 1.6 or pH 5.0.
Ecabet also inhibited pepsin activity in the basal gastric juice samples, with 55p20 % and 56.7p15.8 % of activity remaining in gastric juice from patients at pretreatment pH values of 1.6 and 5.0 respectively. Pepsin activity in basal gastric juice samples from healthy volunteers was also inhibited by preincubation with 5 mg\ml ecabet, with 74p8.2 % and 76.3p10.9 % of pepsin activity remaining at pH 1.6 and pH 5.0 respectively. However, because only three basal samples were available for each group, no statistical analysis was carried out. Table 2 shows the percentage inhibition of isoenzyme proteolytic activities by 5 mg\ml ecabet at incubation pH values of 1.6 and 5.0. Pepsin 1 showed the greatest inhibition by ecabet at pH 5.0 (66 %), followed by pepsin 3 (47 %) and pepsin 5 (42 %). Ecabet inhibited a 400 µg\ml pepsin solution by 264.7p31.4 µg\ml for pepsin 1, by 189p33.7 µg\ml for pepsin 3 and by 169p12.4 µg\ml for pepsin 5 (n l 3). Ecabet inhibited pepsin 1 to a significantly greater extent than pepsin 5 at pH 5.0 (P l 0.04), but there was no significant difference compared with pepsin 3. Preincubation of the pepsins with 5 mg\ml ecabet at pH 1.6 again showed most inhibition of pepsin 1 (100 %), compared with 88 % and Pepsin solutions containing 200 or 400 µg were incubated with or without ecabet sodium (5 mg/ml) at pH 1.6 or pH 5.0 (final volume 1 ml). Pepsin activity was measured using the N-terminal assay, and levels were calculated using a pig pepsin standard curve. The studies were carried out with three different preparations of each isoenzyme, and each preparation was measured in triplicate. HPLC data confirmed that pepsin 1 interacts strongly with ecabet. When gastric juice was preincubated with ecabet and chromatographed, it showed a 50 % loss of the pepsin 1 peak (results not shown). Table 3 shows that mucolytic activity measured at pH 1.6 was significantly inhibited in the gastric juice from reflux oesophagitis patients, but not in that from controls. Mucolytic activity in both pentagastrin-stimulated and basal juice samples from patients was significantly decreased by preincubation with ecabet sodium (onetailed Wilcoxon paired analysis ; P l 0.004 and P l 0.03 respectively). These data confirm that ecabet can bind to and inhibit pepsin in human gastric juice.
Inhibition of individual pepsin isoenzymes by ecabet
Inhibition of mucolytic activity of gastric juice
Mucin-ecabet interactions
Viscosity studies demonstrated that ecabet and mucin form complexes in solution, as their measured viscosity is Inhibition of pepsin by ecabet sodium Table 3 Effects of ecabet on mucolytic activity Gastric juice (pH 4.0) was incubated with ecabet, and mucolytic activity was assessed at pH 1.6 by the decrease in viscosity over the first 1 h of a solution of 4-6 mg/ml pig gastric mucin. Results were corrected for controls containing mucin alone. The prefix P denotes a patient with reflux oesophagitis, and the prefix V denotes a nonsymptomatic volunteer. N.E.S., not enough sample.
Decrease in viscosity at pH 1.6 (%) 
Figure 2 Mucin-ecabet interaction studies
Evidence of an interaction was assessed by measuring the specific viscosity at 37 mC of a 5 mg/ml gastric mucin solution mixed with ecabet sodium at concentrations between 0.5 and 10 mg/ml.
greater than that of the individual components (Figure 2 ). At 5 mg\ml mucin and 5 mg\ml ecabet, there was 28.8 % and 19.8 % synergism at pH 5.0 and pH 1.6 respectively. The interaction was dependent on the ecabet concentration and the pH. At pH 5.0, the amount of interaction increased with increasing ecabet concentrations, to a maximum of 32.2 % at 10 mg\ml (the highest concentration used). At pH 1.6 the interaction increased to a maximum (19.8 %) at 5 mg\ml ecabet, and then fell to 7.7 % at 10 mg\ml ecabet.
DISCUSSION
Pepsin, acid and probably Helicobacter pylori are major factors in peptic ulcer disease and reflux oesophagitis [24, 25] . Therefore any agent that inhibits the action of these factors would be useful in the treatment of upper gastrointestinal disease. Ecabet sodium has already been shown to inhibit Helicobacter pylori mucosal adhesion and urease activity [6] [7] [8] , and to inhibit pig pepsin\ pepsinogen activity and pepsin activity in rat gastric juice. If ecabet could also be shown to be an effective inhibitor of human pepsins in gastric juice, in particular the ulcerassociated pepsin 1, and to prevent mucolysis of the protective mucus barrier in the stomach and duodenum, the rationale for its use would be strengthened. The situation pertaining to the oesophagus in inflammation caused by the reflux of gastric juice is different from that in the gastroduodenal mucosa, because the oesophagus is not protected by a dynamic mucus layer [26] . The obvious treatment would be to prevent reflux, but if this cannot be achieved, then inhibition of pepsin activity\ secretion and neutralization of acid\inhibition of acid secretion would be the next best approach.
In the present study we have investigated the potential of ecabet sodium to inhibit proteolytic and mucolytic activities in gastric juice, and its ability to strengthen the gastric mucus barrier. Previously it has been shown that ecabet can inhibit enzyme activity by binding to enzyme protein and precipitating it, thus preventing interaction with its substrate [11] . The greatest degree of binding occurs below pH 2.0. It did, however, depend on the interacting species, i.e. binding was greater and more pHdependent with human serum albumin and fibrinogen than with degraded pig mucin and pepsin [27] . This pH effect was why we used pH values of 1.6 and 5.0 to investigate inhibition and binding in the present study. Ito et al. [11] showed 96 % inhibition of pig pepsinogen pepsin activity, compared with a value of 85 % reported here, following preincubation with 5 mg\ml ecabet at neutral pH. There was little or no effect on a pepsin solution preincubated with ecabet at concentrations up to 10 mg\ml. This was again in agreement with Ito et al. [11] , who measured 10 % inhibition following preincubation with 10 mg\ml ecabet at pH 1.6. These results show that ecabet binds much more efficiently to pepsinogen than to pepsin, precipitating it from solution. The reason for this difference in binding could be twofold : (1) the peptide cleaved off when pepsinogen is converted into pepsin has a high affinity for ecabet, and\or (2) pepsinogen has a different conformation at pH 7.4 to pepsin at pH 1.6, and the change occurs during acid-induced activation. The differences in conformation may explain differences in binding.
Using the more sensitive N-terminal proteolysis assay, ecabet significantly inhibited proteolytic activity in the gastric juice from both patients with reflux oesophagitis and non-symptomatic volunteers. The inhibition of pepsin activity in gastric juice was independent of the pH, and activity in pentagastrin-stimulated gastric juice from patients was inhibited to a significantly greater extent than that in pentagastrin-stimulated juice from volunteers. This trend was also seen with the unstimulated basal gastric juice samples. These results demonstrate a difference in the type of pepsin activity in reflux gastric juice compared with normal juice, and imply that ecabet has the potential to reduce the oesophagal-mucosa-damaging effects of gastric juice in reflux disease. Human gastric juice contains at least seven different pepsins : 1, 2, 3, 3a, 4, 5 and 6 [16] . The majority of the proteolytic activity is due to pepsin 3 (70 %) and pepsin 5 (17 %) [28] . Pepsin 1, a complex of protein and proteoglycan, constitutes only 3.6 % of the total pepsin activity in stimulated gastric juice from normal subjects, but its levels are 4-5 times greater in stimulated gastric juice from patients with peptic ulcer [17, 22] .
Therefore pepsin 1 has been referred to by some authors as the ' ulcer-associated pepsin ', and gastric juice containing increased levels of this enzyme has an enhanced ability to degrade the protective mucosal barrier [18] . It is therefore pertinent to determine the ability of ecabet to inhibit the different pepsins. Ecabet at 5 mg\ml resulted in major inhibition of the three isoenzymes, with values ranging from 42 % to 100 %. These substantial inhibitions occurred at concentrations of pepsin (0.2-0.4 mg\ml) within the range demonstrated to be present in human gastric juice. A statistical comparison of the inhibition of pepsins 3 and 5 by ecabet can be made between the two pH values, even though the pepsin concentrations varied 2-fold, if absolute amounts of pepsin inhibited are compared. The degree of inhibition of pepsins 3 and 5 was unaffected by the pH of the incubation with ecabet. This means that ecabet should be effective in inhibiting human gastric juice pepsin activity, irrespective of the isoenzyme composition or pH. Pepsin 1 was inhibited to the greatest extent by ecabet at both pH values, and this was significant compared with the inhibition of pepsin 5 at pH 5.0. A statistical comparison of the inhibition of pepsin 1 by ecabet at pH 1.6 with that of the other pepsins could not be carried out, because complete inhibition occurred with 200 µg of the enzyme, and more enzyme may have been inhibited by 5 mg\ml ecabet if the pepsin concentration had been raised. For the same reason, a comparison of the inhibition of pepsin 1 by ecabet between the two pH values could not be made. Further experiments with pepsin 1 could not be undertaken, as not enough was available, and its isolation from gastric juice in milligram quantities is an extensive undertaking.
The greater inhibition of pepsin 1 could be explained by the composition of this isoenzyme, which contains 50 % carbohydrate and one or two phosphate groups which may enhance ecabet binding. The binding of ecabet to other biomolecules varies depending on their net charge. This enhanced inhibition of pepsins, and in particular pepsin 1, could go some way to explaining why combination therapy with ecabet and ranitidine resulted in a lower rate of recurrence of peptic ulcer than treatment with ranitidine alone in H. pylori-positive patients [29] .
Mucus is the first line of defence in the stomach and duodenum against the damaging effects of gastric juices. The mucus layer is maintained by a balance between secretion by the epithelial cells and its erosion from the surface. This balance is swung in favour of degradation and erosion in peptic ulcer disease [18] . If ecabet is to enhance protection of the mucosa, it must be able to strengthen the mucus barrier and reduce its breakdown by mucolysis. Here we have shown that ecabet can indeed inhibit proteolytic activity in gastric juice from patients with reflux oesophagitis, and it can also strengthen the mucus barrier in the stomach and duodenum via an interaction with mucin. In addition, intragastric administration of ecabet has been shown recently to stimulate mucin biosynthesis and secretion in the rat stomach [30] . The results presented here show that ecabet may be useful in the treatment of peptic ulcer disease and reflux oesophagitis, in that it will effectively inhibit pepsin and pepsinogen at the pH values likely to be present in the stomach, duodenum and oesophagus, and thereby reduce damage to the gastroduodenal mucus barrier and to the oesophagal mucosa. Ecabet may be of particular relevance in the treatment of reflux oesophagitis, where pepsin and acid are major aggressive factors. In addition, further work is needed to investigate why ecabet is better at inhibiting proteolytic and mucolytic activity in gastric juice from patients with reflux oesophagitis than in that from healthy volunteers. One possibility is that an H. pylori infection in the oesophagitis patients may modify pepsin secretion, and that this or another mechanism may have resulted in a different pepsin isoenzyme profile. Unfortunately, the H. pylori status of the patients was not measured in the present study.
